Business segment information (Tables)

9 Months Ended

Sep. 28, 2014

Segment Reporting [Abstract]

Segment Results

The following tables present the Company’s segment results for the three and nine months ended September 28, 2014 and September 29, 2013:

	Three Months Ended				Nine Months Ended
	September 28, 2014		September 29, 2013		September 28, 2014		September 29, 2013
	(Dollars in thousands)
Revenue
Vascular North America	$	63,792	$	55,058	$	190,485	$	168,478
Anesthesia/Respiratory North America	54,699		53,842		164,462		170,532
Surgical North America	36,127		34,147		109,327		108,584
EMEA	141,146		132,265		446,061		412,525
Asia	62,035		55,263		174,176		148,040
OEM	39,174		33,774		108,966		97,222
All other	60,200		49,447		170,347		140,351
Consolidated net revenues	$	457,173	$	413,796	$	1,363,824	$	1,245,732

	Three Months Ended						Nine Months Ended
	September 28, 2014			September 29, 2013			September 28, 2014			September 29, 2013
	(Dollars in thousands)
Operating Profit
Vascular North America	$	11,870		$	6,042		$	31,250		$	17,394
Anesthesia/Respiratory North America	9,421			3,541			21,401			18,483
Surgical North America	12,394			10,333			37,308			37,646
EMEA	28,810			21,074			85,771			65,542
Asia	14,785			18,894			44,718			44,961
OEM	9,651			6,684			24,551			20,778
All other	12,441			11,071			32,564			22,593
Total segment operating profit (1)	99,372			77,639			277,563			227,397
Unallocated expenses (2)	(17,437		)	(11,597		)	(61,856		)	(48,200		)
Income from continuing operations before interest, loss on extinguishments of debt and taxes	$	81,935		$	66,042		$	215,707		$	179,197

(1) Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved.

(2) Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and other impairment charges.

	Three Months Ended				Nine Months Ended
	September 28, 2014		September 29, 2013		September 28, 2014		September 29, 2013
	(Dollars in thousands)
Depreciation and Amortization
Vascular North America	$	7,921	$	7,222	$	23,842	$	20,656
Anesthesia/Respiratory North America	5,321		3,948		13,457		10,663
Surgical North America	909		2,476		4,944		7,708
EMEA	9,688		7,035		28,298		20,666
Asia	2,003		1,134		6,146		3,506
OEM	1,651		1,123		4,715		3,370
All other	4,946		4,137		14,852		12,466
Consolidated depreciation and amortization	$	32,439	$	27,075	$	96,254	$	79,035

Schedule Of Revenues And Property Plant Equipment By Geographic Region

The following table provides total net revenues for the three and nine months ended September 28, 2014 and September 29, 2013 and total net property, plant and equipment by geographic region as of September 28, 2014 and December 31, 2013:

	Three Months Ended				Nine Months Ended
	September 28, 2014		September 29, 2013		September 28, 2014		September 29, 2013
	(Dollars in thousands)
Net revenue (based on selling location)
United States	$	231,278	$	205,049	$	676,088	$	623,397
Other Americas	14,440		12,108		44,399		40,786
Europe	157,797		137,848		500,763		419,062
All other	53,658		58,791		142,574		162,487
	$	457,173	$	413,796	$	1,363,824	$	1,245,732

Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country

	September 28, 2014		December 31, 2013
	(Dollars in thousands)
Net property, plant and equipment
United States	$	201,045	$	203,985
Czech Republic	38,728		41,607
Malaysia	35,972		29,313
All other	71,488		50,995
	$	347,233	$	325,900